HIV

Gilead Confirms HIV Prevention Program Will Continue in Low-Income Countries — Check What It Means Amid Funding Concerns

Gilead will continue its HIV prevention rollout in low-income countries with lenacapavir — a twice-yearly injectable showing near-100% efficacy — despite global health funding cuts. The plan includes 2 million people in 18 countries and partnerships with six generic manufacturers. With FDA approval expected June 2025, this game-changing PrEP drug may reshape global HIV prevention.